KSILINK

Ksilink is a drug discovery company that utilizes a proprietary AI-enabled phenotypic screening platform to identify novel therapeutic candidates. The company specializes in human patient-derived cellular disease models, which it automates for large-scale, high-throughput screening. By integrating morphometric profiling, deep learning, and advanced image mining, Ksilink captures complex disease biology to identify druggable targets and efficient compounds, aiming to establish human proof-of-concept early in the development process. The company operates through a hybrid model, advancing its own proprietary CNS pipeline while also engaging in strategic collaborations across various therapeutic areas.

By leveraging these patient-based models, Ksilink addresses significant unmet medical needs and seeks to reduce high failure rates often associated with traditional, less predictive preclinical models. Their approach allows for the systematic investigation of drug candidates, including small molecules and genetic modalities, by observing phenotypic shifts in diseased cells toward healthy states. This capability is supported by a robotic screening facility and expertise in interpreting large biological datasets, enabling the company to provide robust, reproducible data to partners and accelerate the transition of candidates toward preclinical and clinical development.